Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix (NASDAQ:FLGT)

Fulgent Genetics (FLGT) Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

You will be redirected in 10 seconds.

liveinternet liveinternet